Correlation Engine 2.0
Clear Search sequence regions

  • antibodies (2)
  • asthma (8)
  • biologics (1)
  • diagnosis (1)
  • female (1)
  • humans (1)
  • liver (2)
  • mepolizumab (6)
  • omalizumab (1)
  • patient (6)
  • woman (1)
  • Sizes of these terms reflect their relevance to your search.

    Background: There is a lack of information about the course of coronavirus disease 2019 (COVID-19) in patients with severe asthma who were treated with biologics. Some reports indicated that treatment with benralizumab, dupilumab, and omalizumab in patients with severe asthma was not associated with significant adverse effects during COVID-19. Methods: Asthma itself or the biologic agents used to treat asthma can have a positive effect on the course of COVID-19. There seem not to be any cases that specifically reported the use of mepolizumab in a patient who was infected with COVID. Results: We reported of a 55-year-old woman with a diagnosis of severe asthma for; 3 years and who was being treated with mepolizumab, with no evidence of loss of asthma control, at the time of contracting COVID-19 and who had been followed up in the allergy clinic. In addition, there are no data on mepolizumab therapy in patients with elevated liver enzyme levels. Conclusion: With this case, we also reported that no adverse effects were observed during mepolizumab treatment in a patient with elevated liver enzyme levels.


    Kurtulu┼č Aksu, Selma Yesilkaya, Musa Topel, Suleyman Turkyilmaz, Dilek Cuhadar Ercelebi, Ali Oncul, Ilkay Koca Kalkan, Hale Ates. COVID-19 in a patient with severe asthma using mepolizumab. Allergy and asthma proceedings. 2021 Mar 21;42(2):e55-e57

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33536114

    View Full Text